AG
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et) | Frontiers in medicine |  | 2022 | 237 | 126 | ||
| c-Maf enforces cytokine production and promotes memory-like responses in mouse and human type 2 innate lymphoid cells | EMBO journal | | 2022 | 381 | 429 | ||
| PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions | Nature Communications | | 2021 | 356 | 239 | ||
| Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment | Cellular & Molecular Immunology | | 2021 | 244 | 127 | ||
| Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment | Cell Stress | | 2020 | 340 | 172 | ||
| Immunosuppressive mediators impair proinflammatory innate lymphoid cell function in human malignant melanoma | Cancer Immunology Research |  | 2020 | 611 | 4 | ||
| Immunophenotyping of human innate lymphoid cells | Methods in Molecular Biology | | 2019 | 331 | 1 | ||
| Peripheral innate lymphoid cells are increased in first line metastatic colorectal carcinoma patients: a negative correlation with th1 immune responses | Frontiers in Immunology | | 2019 | 328 | 136 | ||
| CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML | Blood Advances | | 2019 | 544 | 247 | ||
| Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis | Nature Communications | | 2017 | 677 | 195 |
